The clinical effects of DC-CIK cells combined with chemotherapy in the treatment of advanced NSCLC

Chinese-German Journal of Clinical Oncology

Volumn 11, Issue 2, 2012, Pages 67-71

  Zhang, Junping ^a   Mao, Guanghua ^a   Han, Yaping ^a   Yang, Xiaoling ^a   Feng, Huijing ^a   Jia, Linzi ^a   Zhi, Ting ^a   Xiao, Yan ^a   Zhang, Libin ^a   Wang, Jiangtao ^a   Shi, Tianliang ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive cellular immunotherapy; Autologous dendritic cells co cultured with cytokine induced killer cells (DC CIK); Chemotherapy; Non small cell lung cancer (NSCLC)

Indexed keywords

CISPLATIN; DOCETAXEL; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CD3+ CD4+ T LYMPHOCYTE; CD3+ CD8+ T LYMPHOCYTE; CD3- CD56+ T LYMPHOCYTE; CHINA; COCULTURE; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE RELEASE; DENDRITIC CELL; DRUG SAFETY; HUMAN; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHYSICAL CAPACITY; QUALITY OF LIFE; SLEEP; SURVIVAL RATE; T LYMPHOCYTE; UNIVERSITY HOSPITAL;

EID: 84860791568     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-011-0929-x     Document Type: Article

References (22)

1. Nagaraj S, Ziske C, Schmidt-Wolf IG. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin- 2 gene transfer. Genet Vaccines Ther, 2004, 2: 12.
2. Yamaguchi Y, Ohshita A, Kawabuchi Y, et al. Adoptive immunotherapy of cancer using activated autologous lymphocytes - current status and new strategies. Hum Cell, 2003, 16: 183-189.
3. Choudhury A, Palma M, Mellstedt H. The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. Clin Lung Cancer, 2008, 9 Suppl 1: S37-44. (Pubitemid 351345726)
4. Tuyaerts S, Van Meirvenne S, Bonehill A, et al. Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol, 2007, 82: 93-105. (Pubitemid 47026420)
5. Märten A, Ziske C, Schöttker B, et al. Interactions between dentritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother, 2001, 24: 502-510. (Pubitemid 33104869)
6. Liu QC, Wu WH, Li GR, et al. Effect of Lingdankang composite combined dendritic cell-cytokine induced killer cells in treating leukemia. Chin J Integ Med (Chinese), 2009, 29: 347-350.
7. Olioso P, Giancola R, Di Riti M, et al. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol, 2009, 27: 130-139.
8. Wang SY, Du WL, Zhang H, et al. Biological characteristics and antitumor activity of CIK cells activated by recombinant human fibronectin for human lung cancer cell lines in vitro. Chin J Lung Cancer (Chinese), 2010, 13: 277-281.
9. Liu M, Xu JW, Jin RM. Biological activity of cytokine-induced killer cells in vitro. J Appl Clin Pediatr (Chinese), 2010, 25: 1144-1147.
10. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: costimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol, 2009, 157: 9-19.
11. Wei XC, Zhai XH, Zhao WL, et al. Research on the biological activity and anti-tumor effect against lymphoma cells of DC-CIK cells. Chinese- German J Clin Oncol, 2008, 7: 666-669.
12. Ren X, Yu J, Liu H, et al. Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biother Radiopharm, 2006, 21: 22-33.
13. Zhang YS, Yuan FJ, Jia GF, et al. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol, 2005, 11: 3339-3345.
14. Kong J, Jiang JT, Wu CP. Correlated clinical factors on the prognosis of gastric cancer patients treated with CIK cell therapy. Chin Clin Oncol (Chinese), 2010, 15: 295-299.
15. Yang T, Xiang Y, Li YC, et al. Clinical study of co-treatment with DCCIK cells for advanced solid carcinomas. Chinese-German J Clin Oncol, 2011, 10: 354-359.
16. Li H, Wang C, Yu J, et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on nonsmall cell lung cancer in patients after surgery. Cytotherapy, 2009, 11: 1076-1083.
17. Wu C, Jiang J, Shi L, et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res, 2008, 28: 3997-4002.
18. Chen HW, Liao CH, Ying C, et al. Ex vivo expansion of dendritic-cellactivated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin- 7, and interleukin-15: potential for adoptive T cell immunotherapy. Clin Immunol, 2006, 119: 21-31. (Pubitemid 43343864)
19. Märten A, Renoth S, von Lilienfeld-Total M, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dentritic cells. Haematologica, 2001, 86: 1029-1037. (Pubitemid 33031868)
20. Liebowitz DN, Lee KP, June CH. Costimulatory approaches to adoptive immunotherapy. Curr Opin Oncol, 1998, 10: 533-541. (Pubitemid 28502247)
21. Shebzukhov YV, Koroleva EP, Khlgatian SV, et al. Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy. Immunol Lett, 2005, 100: 88-93. (Pubitemid 41262038)
22. Oosterwijk E, Divgi C, Bandert NH. Active and passive immunotherapy: vaccines and antibodies. BJU Int, 2007, 99: 1301-1304. (Pubitemid 46624179)